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Abstract In the present paper we have analyzed uPAR-
mediated cellular binding to vitronectin using the murine
erythroid progenitor cell line 32D. We show that expression of
uPAR in 32D cells promotes cellular binding to vitronectin, but
fails to support cell spreading. The strength of binding is
correlated to the expression level of uPAR and is strongly
stimulated by the presence of uPAR ligands. Using a truncated
variant of uPAR lacking domain 1 and by antibody inhibition
experiments, we demonstrate that domain 1 plays a crucial role
in uPAR-mediated cellular binding. The failure of the mutant
uPAR to promote cellular binding is paralleled by a strong
reduction in the affinity for vitronectin in vitro.
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1. Introduction
The presence of a cellular proteolytic variant of uPAR com-
posed of domain 2 and 3 (D2D3) and, thus, lacking the major
uPA binding domain 1 (D1), was ¢rst identi¢ed in U937 cells
[1] and has since then been observed in other cell lines and
tumor extracts [2,3]. The formation of the D2D3 uPAR var-
iant may involve the proteolytic cleavage by uPA, which is
capable of cleaving the receptor in the linker region between
domain 1 and 2 both in vitro and at physiological concentra-
tions in vivo [1,4]. The cleavage of uPAR in this region results
in profound changes in the biological properties of uPAR:
¢rst, uPAR loses the capacity to bind uPA with a concomitant
loss of potential to enhance uPA-mediated cell surface plas-
min generation [4,5]. Since the cleavage is mostly expected to
occur under conditions of high uPA activity, it might function
as a negative feedback mechanism regulating cell surface pro-
teolysis [4]. Second, the cleavage in the hinge region unmasks
bioactive epitopes of uPAR that have the potential to induce
cellular chemotaxis, cytoskeletal reorganisation and activation
of kinases from the src-family [6^8].
Cellular binding to vitronectin, mediated by uPAR, was
¢rst shown in the human histiocytic lymphoma cell line
U937. This cell line becomes strongly adhesive to vitronectin
when stimulated with a combination of vitamin D3 and trans-
forming growth factor L1 or with phorbol esters [9,10]. This
has later been extended to other cell lines and it has been
shown that both cellular and soluble uPAR interact directly
with certain forms of vitronectin [10^12]. Besides mediating
cellular binding to vitronectin uPAR also modulates the func-
tion of adhesion receptors from the integrin family [13^16]
and data for a direct interaction between uPAR and puri¢ed
Mac-1 have been presented [13]. The region of uPAR respon-
sible for the interaction with vitronectin was initially assigned
to D2D3 [11] but later data obtained using real-time biomo-
lecular interaction analysis have demonstrated that also D1 is
required for the high-a⁄nity interaction in vitro [12]. At
present, only little data on the e¡ect of cleavage on the po-
tential of uPAR to mediate cellular binding to vitronectin
have been presented [3].
In this paper we analyze the potential consequence of
uPAR cleavage on the a⁄nity for vitronectin and on the ca-
pacity to mediate cellular binding to vitronectin. Using cellu-
lar and soluble uPAR mutant receptors we report that D1
plays a crucial role for the capacity of uPAR to mediate
cellular binding to vitronectin as well as for the high a⁄nity
interaction with vitronectin in vitro. The system employed,
32D erythroid progenitor cells, is suitable for this analysis
as these cells display low intrinsic, integrin-mediated binding
to the extracellular matrix proteins ¢bronectin and vitronec-
tin. Thus, the uPAR-mediated binding is not confused with
possible integrin-mediated cell binding and is not a¡ected by
cell spreading.
2. Materials and methods
2.1. Reagents
The 32D and WEHI-1 cell lines were obtained from Dr. Jacalyn H.
Pierce. COS7 cells were obtained from the American Type Culture
Collection (Rockville, MD, USA). General chemicals used in this
study were obtained from Sigma or Boehringer Mannheim and were
of the highest available quality. Cell culture reagents (RPMI, gluta-
mine, penicillin, streptomycin, FCS, trypsin) were purchased from
Gibco-BRL, Italy. Recombinant murine IL-3 was obtained from
Boehringer Mannheim, Italy. Tissue culture plastic ware was from
Costar, Italy. Monoclonal mouse antibodies against human uPAR
(mAb: R2, R3, R4 and R5) were obtained from Dr. Gunilla HÖjer-
Hansen at the Finsen Laboratory in Denmark. Monoclonal mouse
antibody directed against the FLAG1-epitope (mAb: M2) was pur-
chased from Sigma, Italy. Rabbit polyclonal antibodies against the
FLAG-epitope were purchased from Santa Cruz Biotechnology,
CA, USA. Human pro-uPA, uPA and ATF was a generous gift of
Dr. Jack Henkin (Abbott Laboratories, IL, USA). Human vitronectin
was obtained from Molecular Innovations, MI, USA. Fibronectin was
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obtained from Boehringer Mannheim, Italy. Oligonucleotides were
purchased from PRIMM (Italy) and GENSET (France) and had
the following sequences (3P^5P) : FRA18: ATTATACTCGAGGAA-
GACGTGCAGGGACCCCGCGCA, FRA19: TATATTGATCATT-
TAGGTCCAGAGGAGAGTGCCTC, D2.5PT: AATGCATTCGA-
GGCCCCAAGAGGCTGGGA.
2.2. Puri¢cation of recombinant soluble uPAR molecules
Cloning and expression of recombinant soluble uPAR mutant pro-
teins was performed as described elsewhere [7]. The recombinant pro-
teins were puri¢ed from COS7 conditioned medium by passage over
an anti-FLAG1 a⁄nity column (M2 A⁄nity gel, Sigma). After wash-
ing of the column with phosphate bu¡ered saline (PBS), the recombi-
nant proteins were eluted using 0.1 M glycine pH 3.0. The fractions
were immediately neutralized using 1/10 volume of 1 M Tris^HCL pH
8.0 and analyzed by enzyme-linked immunosorbent assay (ELISA).
Fractions containing the recombinant protein were pooled and dia-
lyzed against PBS.
2.3. General cell culture
All cell culture media used were supplemented with glutamine
(5 mM), penicillin (100 U/ml) and streptomycin (100 Wg/ml). WEHI-
1 cells were cultured in complete RPMI medium containing 15% FCS.
32D cells were cultured in complete RPMI medium supplemented
with 10% FCS and 10% WEHI-1 conditioned medium as a source
of IL-3. For the reparation of conditioned WEHI medium, cultures of
proliferating WEHI-1 cells were split 1:100 in fresh medium and al-
lowed to grow until the medium turned acidic (5^6 days). Cells were
pelleted by centrifugation and the conditioned medium sterile ¢ltered
(0.2 Wm) and stored at 4‡C until use.
2.4. Construction of expression vectors
Vectors expressing the wild type receptor (uPAR) and a deletion
mutant lacking the ¢rst 92 amino acids corresponding to domain 1
(D2D3) were constructed by ¢rst amplifying the entire uPAR cDNA
[17] with the primers FRA18 and FRA19 and cloning the product in a
EcoRV digested and T-tailed pBluescript SK- vector. The expression
vector LTR-2/uPAR was generated by transferring a XhoI^ClaI frag-
ment, containing the entire uPAR-coding region, from the pBluescript
sub-clone to the LTR-2 expression vector digested with same enzymes.
The LTR-2/D2D3 expression vector was constructed by ¢rst replacing
the NruI^NsiI fragment (containing the entire D1 coding region) of
the pBluescript uPAR sub-clone with a PCR product generated by
ampli¢cation of the uPAR cDNA with the primers FRA18 and
D2.5PT and digested with the same enzymes (thereby restoring the
desired signal-peptide/D2D3 junction amino acid 31/93). Finally,
the modi¢ed uPAR cDNA was transferred to the LTR-2 vector as
described for the wild type cDNA.
2.5. Transfection of 32D cells
32D cells were harvested in mid-log phase (0.5U106/ml) and
washed twice in RPMI medium. Cells were resuspended in RPMI
(50U106/ml) and 0.2 ml aliquots were added to electroporation cu-
vettes (0.4 cm, Bio-Rad) already containing 20 Wg of the desired ex-
pression vector and 2 Wg of pRSVneo (1 Wg/ml in water). Cells were
electroporated using a single 280 V, 960 WF pulse in an electropora-
tion apparatus (Bio-Rad, Gene Pulser II) and transferred to complete
medium for recovery. After 48 h cells were transferred to complete
medium containing 0.8 mg/ml G418 for selection of stable transfec-
tants. Single clones of transfectants were obtained by limited dilution
of G418 resistant pools into 96-well tissue culture plates. Stable pools
and clones of transfected 32D cells were maintained under weak se-
lective pressure in medium containing 0.2 mg/ml G418.
2.6. Adhesion assays
The coating of 96-well tissue culture dishes was performed by in-
cubation with 5 Wg/ml vitronectin or 10 mg/ml ¢bronectin in PBS for
2 h at 37‡C or overnight at 4‡C. The remaining binding sites were
saturated by incubation of the wells with 2% bovine serum albumin in
PBS for 1 h at 37‡C. Immediately before the adhesion assay, cells
were washed twice in RPMI containing 0.1% bovine serum albumin
(BSA) and resuspended in the same medium at 2U106/ml. Cells (0.05
ml) were added to wells already containing 50 Wl RPMI with 0.1%
BSA and the agonists/antagonists to be tested. The plates were cen-
trifuged at 1000 rpm for 1 min to sediment the cells and incubated in
a humidi¢ed incubator at 37‡C for 1 h. At the end of the incubation
the wells were washed with 37‡C-warm RPMI as follows: to the
medium already present in the wells was added 2U100 Wl medium,
at normal pipetting speed, using a multi-well pipette, row by row and
from two opposite sites of the wells. The medium (containing the
suspended non-adherent cells) was then immediately aspirated from
one side of the well and 100 Wl of fresh medium added. The procedure
of washing was repeated, if necessary, until BSA coated wells con-
tained only a few remaining cells. Adherent cells were ¢xed for 10 min
with 37‡C-warm PBS containing 3% (w/v) formaldehyde and the cells
stained for 5 min with crystal violet solution (0.5% (w/v) in 20% (v/v)
methanol). After washing of the plate by immersion in tap-water, the
cells were lyzed in 1% SDS in water and the absorption at 540 nm was
measured in an ELISA plate reader. To obtain a measure for speci¢c
adhesion the readings were subtracted from the value obtained in
BSA coated wells, unless otherwise indicated. All experiments were
performed at least three times and the shown values are the
mean þ S.D. of triplicate or quadruplicate determinations from a rep-
resentative experiment.
2.7. FACS analysis
32D cells to be analyzed (1U106) were pelleted by centrifugation
and resuspended in 0.1 ml ice-cold wash bu¡er (PBS containing 5%
FCS) containing 10 mg/ml of the R2 monoclonal antibody and in-
cubated on ice for 30 min. The cells were washed twice with 3 ml ice
cold wash bu¡er and resuspended in 0.1 ml wash bu¡er containing a
FITC conjugated goat anti-mouse antibody (DAKO) diluted 1:50 in
wash bu¡er and incubated for 20 min on ice. After another round of
washing, the cells were resuspended in 0.5 ml PBS and analyzed in a
Becton Dickinson £ow cytometer according to the manufacturers in-
structions. Relative values for the mean £uorescence were calculated
using the Lysis II software package. Non-transfected cells were used
as controls for speci¢city.
2.8. In vitro binding assays
ELISA plates (Nunc Maxisorb) were coated with vitronectin (0.1
ml, 5 Wg/ml) in PBS for 2 h at 37‡C or overnight at 4‡C. The remain-
ing protein binding sites were blocked using 1% blocking reagent
(Boehringer Mannheim) in TBS for 1 h at room temperature. All
further incubations were performed with gentle agitation at room
temperature in 0.1 ml TBS containing 1% blocking reagent (Boehr-
inger Mannheim) and followed by extensive washing with TBS con-
taining 0.1% Tween-20. First, wells were incubated with the FLAG1-
tagged soluble uPAR molecules diluted to the indicated concentra-
tions for 1 h at room temperature. In some cases the recombinant
suPAR was co-incubated with pro-uPA, ATF and/or antibodies.
After washing, wells were probed for the FLAG-epitope by incuba-
tion with 0.2 Wg/ml rabbit anti-FLAG antibody (Santa Cruz, #sc-807)
for 1 h. After washing, wells were probed for bound antibody by
incubation with a horseradish conjugated goat anti-rabbit antibody
(Amersham) diluted 1:1000. After another round of washing, bound
horseradish conjugate was quanti¢ed by colorimetric development
using the chromogenic substrate ABTS (Boehringer Mannheim).
The absorption at 436 nm was recorded in an ELISA plate reader
and the signal obtained from wells that were coated with blocking
reagent subtracted.
3. Results
3.1. Adhesive properties of 32D cells
To analyze the structural requirements of uPAR as an ad-
hesion receptor we needed a cell system that ful¢ls two cri-
teria. First, the cell line should be easy to transfect and second
the cell line should have low basal binding to vitronectin in
order to discriminate between binding caused by the trans-
fected molecules and binding caused by endogenously ex-
pressed adhesion receptors.
To evaluate the murine myeloid 32D cell line as a model
system for uPAR-mediated adhesion we confronted the adhe-
sive properties of these cells with those of the well-character-
ized human myeloid U937 cells (Fig. 1A). While U937 cells
displayed signi¢cant binding to both ¢bronectin and vitronec-
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tin, 32D cells completely failed to adhere to vitronectin and
only displayed moderate binding to ¢bronectin. Stimulation
with cytokines or phorbol ester (12-O-tetradecanoylphorbol-
13-acetate, PMA) is known to enhance the cellular binding of
U937 cells to vitronectin as a result of enhanced expression of
uPAR and of its ligand uPA [10]. To analyze the e¡ect of
PMA stimulation on the cellular binding of 32D cells we
stimulated cultures of 32D and U937 with PMA for 18 h prior
to the adhesion assay (Fig. 1B). While the treatment with
PMA stimulated the binding of U937 cells to vitronectin ap-
proximately two-fold it failed to modulate the binding of the
32D cells to any of the substrates. The 32D cells express a
range of integrin receptors including ¢bronectin and vitronec-
tin receptors [18,19]. The activation state of the integrin re-
ceptors and the binding to ¢bronectin of 32D cells is regulated
by IL-3 [19]. To analyze the e¡ect of IL-3 stimulation on
binding to ¢bronectin and vitronectin we performed adhesion
assays where the 32D cells had been IL-3-starved for 8 h prior
to the experiment (Fig. 1C). Under these conditions the re-
addition of IL-3 stimulated the cellular binding of 32D cells to
¢bronectin approximately two-fold, but failed to modulate the
binding to vitronectin.
From these experiments we conclude that the 32D cells
represent a suitable model system for the analysis of uPAR-
mediated cellular binding to vitronectin as they do not display
any notable binding to vitronectin independently of the acti-
vation state.
3.2. uPAR expression promotes 32D cell binding to vitronectin
To analyze uPAR-mediated cell binding we transfected 32D
cells with an expression vector in which we had engineered the
full-length human uPAR cDNA [17]. By selection of the
transfected cells with G418 we obtained a pool of resistant
cells representing a population of clones expressing variable
amounts of uPAR on the cell surface as determined by FACS
analysis using the anti-uPAR monoclonal antibody R2 (re-
sults not shown). During normal passage, the pool of
uPAR-transfected cells was notably more adherent to the tis-
sue culture plates than mock-transfected cells (results not
shown). To investigate if the increased binding of the
uPAR-transfected cells was mediated by vitronectin present
in the culture medium we performed adhesion assays to puri-
¢ed vitronectin immobilized in 96-well tissue culture plates
under serum free conditions (Fig. 2). Indeed, the pool of
uPAR-transfected cells bound stronger to vitronectin than
mock-transfected cells over a range of coating concentrations,
demonstrating that the expression of uPAR in 32D cells pro-
motes cell binding to vitronectin.
3.3. The strength of cell binding to vitronectin correlates with
the expression level of uPAR
Even at the highest vitronectin coating concentration less
than 10% of the cells in the pool of uPAR transfectants re-
mained bound after washing (not shown) and we speculated
that this was caused by the heterogeneous uPAR expression in
the pool. To analyze the relationship between the expression
level of uPAR and the strength of binding to vitronectin we
therefore cloned the pool of transfected cells by end-point
dilution. A number of clones representing a range of uPAR
expression levels (Fig. 3A) were selected for analysis and their
binding to vitronectin determined (Fig. 3B). There was a good
Fig. 1. Adhesive properties of 32D and U937 cells. Non-stimulated
(A) or PMA-stimulated (B) 32D cells (closed bars) and U937 cells
(open bars) were allowed to adhere to wells coated with ¢bronectin,
vitronectin or BSA under serum free conditions. After 1 h, the wells
were washed and bound cells ¢xed and stained. The numbers of
bound cells (in arbitrary units) were calculated by measuring the ab-
sorbancy at 540 nm and subtracting the value obtained from wells
that received no cells. C: Binding of IL-3-starved 32D cells to vitro-
nectin and ¢bronectin in the absence (open bars) or presence (closed
bars) of 100 U/ml recombinant mouse IL-3. Bound cells were quan-
ti¢ed as before and the value obtained in wells coated with BSA
subtracted. The data represent the mean þ S.D. of triplicate determi-
nations from a representative experiment.
Fig. 2. Expression of uPAR in 32D cells causes increased binding to
vitronectin. Pools of G418 resistant cells obtained after transfection
with an uPAR expression vector (circles) or empty expression vector
(squares) were allowed to adhere to wells coated with increasing
concentrations of vitronectin and the bound cells were quanti¢ed as
before.
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correlation between the expression level of uPAR and the
strength of binding to vitronectin as higher expression levels
of uPAR were associated with stronger binding to vitronectin.
In the highest expressing clones more than 90% of the cells
remained bound after washing of the plates (not shown),
while the lowest expressing clone (c21) displayed binding com-
parable to that of the pool of transfected cells. Two clones
(c14 and c17) did not express detectable levels of cell surface
uPAR as evaluated by FACS analysis and were included in
the analysis as negative controls.
3.4. Cell binding is stimulated by uPAR ligands
uPAR-mediated binding of U937 cells to vitronectin is
stimulated by uPA [10] and we therefore analyzed the e¡ect
of uPA on the binding of uPAR-transfected 32D cells to vi-
tronectin (Fig. 3B). Clones expressing high levels of uPAR
bound strongly to vitronectin in the absence of ligand and
the addition of pro-uPA to the assay only slightly stimulated
binding. However, the binding of clones expressing low and
intermediate levels of uPAR was stimulated by pro-uPA and
the stimulation was inversely correlated with the expression
level of uPAR. A clone expressing low levels of uPAR (c21)
was strongly stimulated and clones expressing intermediate to
high levels of uPAR (c8, c2, c22 and c1), only weakly stimu-
lated. The presence of pro-uPA during the adhesion assays
had no signi¢cant e¡ect on the negative control clones ex-
pressing undetectable levels of uPAR (c14 and c17), demon-
strating that the stimulatory e¡ect of pro-uPA was indeed
mediated by uPAR. Stimulation of binding to vitronectin by
pro-uPA was dose-dependent with a half-maximal e¡ect at
0.1^0.3 nM pro-uPA (not shown), consistent with the Kd for
the interaction between uPAR and pro-uPA. Also two-chain
uPA and the amino-terminal fragment (ATF) of uPA stimu-
lated the binding with equal e⁄ciency (results not shown)
demonstrating that it was the ligand binding capacity, rather
than the catalytic activity that was responsible for the en-
hancement of binding (not shown).
3.5. Domain 1 of uPAR is required for cell binding to
vitronectin
To analyze the e¡ect of uPAR cleavage on uPAR-mediated
cell binding to vitronectin we constructed a mutant uPAR
cDNA encoding a deletion variant of uPAR where the region
encoding domain 1 (amino acids 1^92) was deleted creating a
receptor composed of domain 2 and 3 (D2D3). The structure
and the domain composition of this recombinant receptor is
equivalent to a cleaved form of uPAR observed on various
cell lines and tumors [1^3]. We generated clones of 32D cells
with the mutant receptor as described for full-length uPAR
and identi¢ed several clones expressing the truncated receptor
at levels comparable to that of full-length uPAR (Fig. 3A).
Even though the D2D3 receptor was e⁄ciently expressed it
completely failed to promote 32D cell binding to vitronectin
(Fig. 3B).
To further analyze the role of domain D1 in uPAR-medi-
ated cell binding to vitronectin, we tested monoclonal anti-
bodies against uPAR for their ability to inhibit the binding of
uPAR-transfected 32D cells (Fig. 4A). We used the 32D/
uPAR clone 1 cells, as these adhere strongly to vitronectin
in the absence of pro-uPA and performed the adhesion assay
in the absence of pro-uPA to avoid interference between anti-
body and pro-uPA binding to uPAR. The possible interfer-
ence by endogenous 32D pro-uPA can be disregarded because
these cells appear not to produce pro-uPA (not shown). In
addition, murine pro-uPA would have about a 1000-fold low-
er a⁄nity for human uPAR [20,21]. Two monoclonal anti-
bodies recognizing epitopes within domain 3 of uPAR (mAb
R2 and R4) and a control antibody (M2) did not a¡ect the
cell binding to vitronectin. However, both antibodies recog-
nizing epitopes within D1 of uPAR (mAb R3 and R5)
strongly inhibited the binding, demonstrating the importance
of this domain in uPAR-mediated cell binding to vitronectin.
3.6. Domain 1 and uPAR ligand are required for high a⁄nity
binding of soluble uPAR to vitronectin in vitro
The above data suggest that the defect of D2D3 receptor to
mediate cellular binding to vitronectin was caused by a re-
duced or abolished ability to interact with vitronectin. To
address this point directly we analyzed if the D2D3 receptor
also has a reduced a⁄nity for vitronectin in vitro. To do this
we performed in vitro binding assays to immobilized vitronec-
Fig. 3. Binding of 32D uPAR/D2D3 clones to vitronectin. Surface
expression (A) of uPAR and D2D3 on cells was evaluated by
FACS analysis using the R2 monoclonal antibody that recognizes
an epitope on domain 3 of human uPAR. The mean £uorescence
(in arbitrary units) is indicated and the clones have been arranged
from left to right in order of increasing expression level. Adhesion
to vitronectin (B): clones of 32D cells transfected with full-length
uPAR (c14, c17, c21, c8, c2, c22, and c1) or with a D2D3 (c18, c6,
c13, and c19) were allowed to adhere to vitronectin under serum
free conditions in the presence (¢lled bars) or absence (open bars)
of 5 nM pro-uPA. Adhesion to ¢bronectin (C) was performed as
for vitronectin with the exception that it was performed after 8 h of
IL-3 starvation and done in the absence (open bars) or presence
(¢lled bars) of 100 U/ml IL-3.
FEBS 23423 9-3-00
N. Sidenius, F. Blasi/FEBS Letters 470 (2000) 40^46 43
tin using a soluble form of full-length uPAR and of the mu-
tant D2D3 receptor. The construction, expression and puri¢-
cation of these soluble receptors have been described in detail
elsewhere [7]. These soluble uPAR variants have the same
domain structure as those used for transfection of 32D cells
but the GPI-anchoring sequence has been replaced with a
short peptide sequence (the FLAG epitope) recognized by
speci¢c antibodies. We incubated vitronectin-coated wells
with increasing concentrations of the recombinant receptors
in the presence or absence of pro-uPA and quanti¢ed the
bound proteins by virtue of the FLAG-tag (Fig. 4B). Even
though we could detect binding of the full-length receptor
down below 1 nM in the presence of pro-uPA we failed to
observe any notable binding in the absence of pro-uPA, sug-
gesting that uPAR occupancy is indeed a major determinant
in the a⁄nity of uPAR for vitronectin. The soluble D2D3
receptor mutant failed to bind to vitronectin over the entire
concentration range and did so both in the presence or ab-
sence of pro-uPA.
3.7. uPAR-mediated binding to vitronectin is independent of
integrin activation state
In uPAR-transfected HEK293 cells uPAR-mediated vitro-
nectin adhesion depends upon integrin activation as it is in-
hibited at low temperatures and by the introduction of dom-
inant negative integrins [13]. To analyze the requirement for
integrin function in the 32D-cell system, we performed adhe-
sion assays in which we regulated the integrin activation state
using IL-3 and temperature (Fig. 5A). The binding to vitro-
nectin was not signi¢cantly a¡ected by IL-3 stimulation and
was not reduced at 4‡C, suggesting that uPAR-mediated cell
Fig. 5. uPAR-dependent vitronectin binding of 32D cells is inde-
pendent of integrin activation and does not lead to cell spreading.
A: IL-3-starved 32D/uPAR clone 1 cells were allowed to adhere to
vitronectin or ¢bronectin in the presence (¢lled bars) or absence
(open bars) of IL-3 (100 U/ml) at 37 or 4‡C as indicated. After
washing, bound cells were quanti¢ed as described in Fig. 1. B:
uPAR-transfected 32D cells (clone 1) were allowed to adhere to
plastic dishes coated with BSA (BSA) or vitronectin (VTN) for 1 h
at 37‡C after which the cells were photographed. To reveal the mor-
phology of cells plated on BSA the dishes were not washed prior to
photography.
Fig. 4. Domain 1 of uPAR is involved in uPAR binding to vitro-
nectin both in vivo and in vitro. A: 32D/uPAR clone 1 cells ex-
pressing high levels of uPAR were allowed to adhere to vitronectin
in the presence of monoclonal antibodies against either uPAR do-
main 3 (mAb R2 and R4), uPAR domain 1 (mAb R3 and R5) or a
negative control antibody (mAb M2). After washing, bound cells
were quanti¢ed as described in the legend to Fig. 1. B: Binding of
soluble uPAR to vitronectin. ELISA plates were coated with vitro-
nectin (5 Wg/ml) and the remaining binding sites blocked with BSA.
Wells were incubated with increasing concentrations of FLAG
tagged soluble uPAR (squares) or D2D3 mutant (circles). The bind-
ing was performed in the presence (¢lled) or absence (open) of 50
nM pro-uPA. After washing, the amount of bound protein was
quanti¢ed by sequential incubations with an anti-FLAG antibody;
a horseradish peroxidase conjugated secondary antibody and a col-
orimetric peroxidase substrate. The absorbancy at 412 nm was
measured in an ELISA reader and taken as a measure of bound
proteins. The data represent the medium value of duplicate determi-
nations ( þ S.D.) from a representative experiment. The curves for
the D2D3 protein cannot be seen very well as they are superim-
posed with the curve for soluble uPAR in the absence of pro-uPA.
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binding to vitronectin does not require integrin activation.
The integrin-mediated binding of 32D cells to ¢bronectin
was enhanced by IL-3 stimulation but this stimulation was
almost completely inhibited at 4‡C demonstrating the require-
ment for metabolic energy in this type of cell binding. Inhibi-
tion of integrin function by EDTA and peptides containing
the RGD motif also failed to inhibit the binding of uPAR-
expressing cells to vitronectin while they completely blocked
the binding to ¢bronectin (not shown). In support of the lack
of integrin involvement in the uPAR-mediated cell binding to
vitronectin we also failed to observe cell spreading of the
uPAR-transfected 32D cells (Fig. 5B).
In HEK293 cells the expression of uPAR inhibits integrin-
mediated adhesion to ¢bronectin, suggesting that uPAR also
regulates cell adhesion by modulation of integrin function
[13]. To investigate if this is also the case in the transfected
32D cells we assayed the binding of the di¡erent 32D clones
to ¢bronectin in the absence or presence of IL-3 (Fig. 3C).
32D clones expressing both uPAR and D2D3 adhered to ¢-
bronectin and binding was further stimulated by IL-3 demon-
strating that the surface expression of uPAR does not strongly
impair IL-3-dependent integrin function and activation. How-
ever, a rather high degree of clonal variation in adhesion to
¢bronectin was observed, preventing the determination of
possible minor e¡ects.
Taken together the data suggest that uPAR-mediated bind-
ing to vitronectin of transfected 32D cells occurs independ-
ently of integrin function and activation and hence may sim-
ply re£ect an a⁄nity between the cells and the tissue culture
plastic mediated by the interaction between uPAR (on the cell
surface) and vitronectin (on the plastic). To investigate this
possibility we performed adhesion assays to plates that we
had coated with monoclonal antibodies against uPAR (Fig.
6). In fact, uPAR-transfected 32D cells adhered strongly to
wells coated with antibodies against both domain 1 (mAb R3)
and domain 3 (mAb R2). The 32D cells transfected with the
mutant D2D3 receptor, which failed to bind to vitronectin
(Fig. 3B), bound to the uPAR antibody directed against an
epitope within domain 3 (mAb R2). The results thus demon-
strated that in 32D cells any high a⁄nity interaction between
a cell surface molecule (namely uPAR) and an immobilized
protein (vitronectin or anti-uPAR antibodies) can mediate
cellular binding, indicating that uPAR acts as a surface bind-
ing site for vitronectin without intrinsic cell adhesion func-
tions.
4. Discussion
Firm cellular attachment to the extracellular matrix is a
complex process, which involves numerous molecular interac-
tions between extracellular proteins, cell surface receptors and
the intracellular cytoskeleton. The process is initiated by the
cellular binding to the extracellular matrix, mediated by the
interaction between cellular receptors and extracellular matrix
proteins and is followed by a complex process of signaling,
receptor activation and cytoskeleton reorganization, eventu-
ally leading to ¢rm attachment and cell spreading.
Expression of uPAR in 32D cells promotes cellular binding
to vitronectin but not cell spreading. This is in contrast to the
epithelial HEK293 cell line in which expression of uPAR leads
to ¢rm cell adhesion and spreading on vitronectin [11]. The
apparent discrepancy between these observations may be
caused by di¡erences between the two cell lines. HEK293
grow ¢rmly adherent and therefore clearly possess the neces-
sary cell program and machinery to promote ¢rm cell adhe-
sion and spreading. The 32D cells are highly undi¡erentiated,
grow in suspension and are only expected to undergo ¢rm
adhesion and cell spreading upon di¡erentiation. It is there-
fore likely that these cells do not possess the required cell
program and/or machinery to support cell spreading. Expres-
sion of uPAR in 32D cells evidently promotes the initial cel-
lular binding to vitronectin, but fails to initiate the process of
cell spreading (Fig. 5B). The strength of binding of uPAR-
transfected 32D cells to vitronectin and anti-uPAR antibodies
was comparable, suggesting that the only requirement for
binding is a su⁄ciently high number of interactions between
the cell and the substrate. When starved 32D cells are treated
with IL-3, they bind more strongly to ¢bronectin (Figs. 1C
and 3C and [19]). However, both basal- and IL-3-stimulated
binding to ¢bronectin is not strongly a¡ected by the expres-
sion of uPAR (Fig. 3C) suggesting that uPAR does not mod-
ulate integrin function in the 32D cells.
The structural requirement for a high a⁄nity interaction
between vitronectin and uPAR has been addressed in a couple
of studies [11,12]. Wei et al. have suggested that a region
within the D2D3 part of uPAR is responsible for the inter-
action. This conclusion is based on experiments with a D2D3
fragment puri¢ed from chymotrypsin-cleaved suPAR and in-
hibition by the R4 antibody (recognizing an epitope within
domain 3). HÖjer-Hansen et al. have, based on real-time bio-
molecular analysis, concluded that intact uPAR is required
for the high a⁄nity interaction between uPAR and vitronec-
tin. Our data are in accordance with the latter, as we do not
observe any signi¢cant binding of D2D3 to immobilized vi-
tronectin. A likely explanation for the discrepancy between
the observations could be the presence of low levels of con-
taminating full-length soluble uPAR in the D2D3 prepara-
tions used by Wei et al. In our experimental set-up this po-
tential problem has been eliminated using recombinant uPAR
fragments expressed in cells that do not produce any full-
length suPAR.
We observe a strict requirement for the pro-uPA to obtain
signi¢cant binding of suPAR to immobilized vitronectin in
vitro. This observation contradicts data published by others
who observe no di¡erence [4] or a moderate to high stimula-
tion [11] by uPAR ligands. The reason for this discrepancy
may lie in the di¡erent assays employed and in the di¡erent
soluble uPAR molecules or vitronectin preparations used in
Fig. 6. Cell binding to anti-uPAR antibodies. 32D cells transfected
with uPAR (¢lled bars) or the mutant D2D3 receptor (open bars)
were allowed to adhere to wells coated with vitronectin or antibod-
ies against uPAR (5 Wg/ml). After washing of the plates bound cells
were quanti¢ed as before.
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the experiments. The binding of suPAR to vitronectin is not a
simple ¢rst order binding reaction and probably involves con-
formational changes of both uPAR and vitronectin [4]. In-
deed, Wei et al. suggest that uPAR is in equilibrium between
a high and a low a⁄nity conformation, with respect to vitro-
nectin binding, which is pushed towards the high a⁄nity state
upon ligand binding. A number of modi¢cations such as radio
labeling, biotinylation or the engineered addition of epitopes
used for puri¢cation and detection can potentially a¡ect this
equilibrium.
In contrast to our data in vitro, we did not observe a strict
requirement for ligand binding in the process of cellular bind-
ing to vitronectin in vivo, except only partially in clones ex-
pressing low uPAR levels. This apparent di¡erence may have
a number of explanations. First, the local concentration of
membrane bound uPAR at the interface between the cell
and the substratum might be high enough to allow a su⁄cient
number of low a⁄nity interactions between uPAR and vitro-
nectin to obtain the required resistance to the hydrodynamic
stress applied in the adhesion assay. Second, the high a⁄nity
conformation of uPAR could be stabilized by the GPI-an-
chor, which is not present on soluble uPAR or by the inter-
action with other membrane proteins. However, these explan-
ations only apply to cells that express high levels of uPAR.
Low-uPAR 32D cells required ligand to bind to vitronectin.
uPAR antagonist are molecules that inhibit the uPA/uPAR
interaction through binding to uPAR. These molecules in-
clude non-catalytic derivatives of uPA (ATF, GFD and de-
rivatives), antibodies as R3 and R5 [22] and di¡erent low
molecular weight compounds [23]. uPAR antagonists are ther-
apeutically interesting as they are able to inhibit tumor growth
and metastasis in certain model systems (reviewed in [24]).
The anti-cancer e¡ect of these molecules has been assigned
to the capacity to block the binding of uPA to uPAR with
its concomitant reduction in plasminogen activation potential
of the cells. However, it is likely that the e¡ect of these com-
pounds might, at least partially, be caused by their pro- or
anti- adhesive properties. A great deal of work is done in the
pharmaceutical industry to develop non-toxic low molecular
weight uPAR antagonists and the 32D/uPAR cell system is
perfect to test the pro- or anti-adhesive properties of these
compounds.
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